Group items tagged

The Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Substance Abuse Prevention (CSAP) is accepting applications for fiscal year (FY) 2018 Strategic Prevention Framework - Partnerships for Success grants. The purpose of this grant program is to address one of the nation's top substance abuse prevention priorities; underage drinking among persons aged 9 to 20. At their discretion, states/tribes may also use grant funds to target up to two additional, data-driven substance abuse prevention priorities, such as the use of marijuana, cocaine, or methamphetamine, etc. by individuals ages 9 and above. SPF-PFS is designed to ensure that prevention strategies and messages reach the populations most impacted by substance abuse. The program extends current established cross-agency and community-level partnerships by connecting substance abuse prevention programming to departments of social services and their community service providers. This includes working with populations disproportionately impacted by the consequences of substance use; i.e., children entering the foster care system, transitional youth, and individuals that support persons with substance abuse issues (women, families, parents, caregivers, and young adults).

Long-term misuse and chronic exposure to abused substances can produce widespread changes in brain structure and function. Although much progress has been made, additional research is still needed to identify the neurobiological changes that result from substance use, and how these changes contribute to substance use disorders. The overarching goals of the research areas described in this FOA are to understand the neurobiological mechanisms underlying substance use disorders, with special emphasis on identifying changes and neuroadaptations that occur during dependence, withdrawal, and relapse to chronic substance use. An understanding of the basic mechanisms underlying substance use disorders can help to identify targets for prevention and treatment interventions. Research utilizing basic, translational, or clinical approaches is appropriate.

The National Institute of Environmental Health Sciences (NIEHS) invites qualified investigators from domestic institutions of higher education to apply to the Superfund Research Program (SRP) R01 Individual Research Project grant program. The mission of the NIEHS is to discover how the environment affects people in order to promote healthier lives. The NIEHS Superfund Research Program (SRP) (http://www.niehs.nih.gov/research/supported/srp/) was established under the Superfund Amendment Reauthorization Act (SARA) Section 311(a), which authorizes NIEHS to implement a university-based program of basic research for the development of: 1) advanced techniques for the detection, assessment, and evaluation of the effect of hazardous substances on human health; 2) methods to assess the risks to human health presented by hazardous substances; 3) methods and technologies to detect hazardous substances in the environment; and 4) basic biological, chemical, and physical methods to reduce the amount and/or toxicity of hazardous substances. SRP's broad scope, as dictated by the SARA mandates, allows NIEHS to support scientific research to address the wide array of scientific uncertainties facing the national Superfund program utilizing biomedical as well as environmental science and engineering approaches. Research supported by the SRP uses mechanistic science as a foundation and, in keeping with the broad research themes of the program mandates, the SRP promotes an interdisciplinary approach to develop solutions for the safe management of hazardous substances with the ultimate goal of improving public health.

As a key activity, INL promotes the development of substance use disorder studies programs at universities around the world to further develop a trained professional workforce for prevention, treatment and recovery programs. In addition, INL encourages applied research to assess the effectiveness of drug demand reduction efforts, advocates government and community support for evidence based drug demand reduction programs, and fosters the development of a worldwide network including professionals and academic experts focused on drug use. The purpose of this project is to promote the creation and networking of substance use disorder studies researchers and programs in universities in Latin America and the Caribbean, Asia and the Pacific, Africa and Eastern Europe. The recipient will also support existing drug use studies programs with technical assistance and mentoring of program directors. In addition, the recipients will advocate for government use of evidence based substance use disorder prevention programs and treatment as well as work towards applied research to advance the substance use disorder field for prevention, treatment and recovery.

With an emphasis on original work that focuses on improving existing analytical methods for detecting particular drugs, developing new analytical methods to test for substances not currently detectable, and discovering cost-​effective approaches for testing widely abused substances across all levels of sport, the following areas of investigation reflect the PCC&'s current research priorities: Developing methods of cost-effective testing to detect and deter the use of banned and illegal substances. Developing testing protocols to detect designer substances used for doping purposes. Improving existing analytical methods to detect particular drugs, ex. GH, IGF-1, EPO, hCG. Developing analytical methods to detect performance enhancing drugs not currently detectable. Longitudinal urinary excretion patterns, metabolism and dose-concentration. Critical reviews to support interpretation of laboratory data. Alternative specimens, (ex. oral fluid, dried blood/plasma spots) for testing. APPLY FOR A GRANT Sign up for our newsletter

The PCC has supported world-class research since 2009, spending more than $8.0 M to support novel science. Research and grant-making are the foundation of the PCC and are the focus of everyday business activity. PCC-supported research contributes to a movement in addressing doping's root causes and ultimately decreasing the use of performance-enhancing drugs by all participants in all sports at all levels of play. With an emphasis on original work that focuses on improving existing analytical methods for detecting particular drugs, developing new analytical methods to test for substances not currently detectable, and discovering cost-effective approaches for testing widely abused substances across all levels of sport, the following areas of investigation reflect the PCC's current research priorities: - Developing methods of cost-effective testing to detect and deter the use of banned and illegal substances. - Developing testing protocols to detect designer substances used for doping purposes. - Improving existing analytical methods to detect particular drugs, ex. GH, IGF-1, EPO, hCG. - Developing analytical methods to detect performance enhancing drugs not currently detectable. - Longitudinal urinary excretion patterns, metabolism and dose-concentration. - Critical reviews to support interpretation of laboratory data. - Alternative specimens, (ex. oral fluid, dried blood/plasma spots) for testing.

With an emphasis on original work that focuses on improving existing analytical methods for detecting particular drugs, developing new analytical methods to test for substances not currently detectable, and discovering cost-effective approaches for testing widely abused substances across all levels of sport, the following areas of investigation reflect the PCC's current research priorities: - Developing methods of cost-effective testing to detect and deter the use of banned and illegal substances. - Developing testing protocols to detect designer substances used for doping purposes. - Improving existing analytical methods to detect particular drugs, ex. GH, IGF-1, EPO, hCG. - Developing analytical methods to detect performance enhancing drugs not currently detectable. - Longitudinal urinary excretion patterns, metabolism and dose-concentration. - Critical reviews to support interpretation of laboratory data. - Alternative specimens, (ex. oral fluid, dried blood/plasma spots) for testing.

The PCC has supported world-class research since 2008, spending more than $18.0 M to support novel science around the world. Research and grant-making are the foundation of the PCC and are the focus of everyday business activity. PCC-supported research contributes to a movement in addressing doping's root causes and ultimately decreasing the use of performance-enhancing drugs by all participants in all sports at all levels of play. Grant Cycle Deadlines: Pre-Applications are due March 1st, July 1st, and November 1st of each year. Applicants invited to submit full applications must do so by April 1st, August 1st, or December 1st, depending on the cycle (30 days after the pre-application due date). With an emphasis on original work that focuses on improving existing analytical methods for detecting particular drugs, developing new analytical methods to test for substances not currently detectable, and discovering cost-effective approaches for testing widely abused substances across all levels of sport, the following areas of investigation reflect the PCC's current research priorities: Developing methods of cost-effective testing to detect and deter the use of banned and illegal substances. Developing testing protocols to detect designer substances used for doping purposes. Improving existing analytical methods to detect particular drugs, ex. GH, IGF-1, EPO, hCG. Developing analytical methods to detect performance enhancing drugs not currently detectable. Longitudinal urinary excretion patterns, metabolism and dose-concentration. Critical reviews to support interpretation of laboratory data. Alternative specimens, (ex. oral fluid, dried blood/plasma spots) for testing. There is no maximum amount for PCC funding, though the average funding amount is $225,000. To date, over 80 projects have been funded in over 14 countries world-wide. Approximately 33% of applicants are awarded PCC funding.

The National Institute on Drug Abuse (NIDA) supports a program of longitudinal cohorts to address emerging and high priority research on HIV/AIDS in the context of injection and non-injection substance abuse.  These cohorts provide a strong resource platform for current and future collaborative efforts with other investigators to address emerging questions related to HIV pathogenesis, prevention, and treatment in the context of substance abuse, as well as to foster the creativity and efficiency of investigator-initiated research projects. The diverse research activities among these cohorts include basic immunologic, and virologic studies, as well as studies on HIV prevention and treatment, and the co-morbidities and co-infections associated with HIV and substance abuse.  NIDA has determined that a coordinating center (CC) is needed in order to take advantage of these rich sources of data and bio-specimens and optimize collaborations among both the cohort investigators and other researchers not funded under the cohort program. In addition, the CC is expected to establish a virtual repository, and facilitate the leadership of the cohorts steering committee (SC), consisting of representatives from the NIDA-funded cohorts and NIDA staff. At this time, NIDA is soliciting  cooperative agreement applications for a CC to support the collaborative efforts of the cohorts that are currently funded by NIDA.

This Funding Opportunity Announcement (FOA) encourages applications to conduct research on the effects of public policies on health-related behaviors and outcomes associated with alcohol, marijuana, and other substances. The purpose of the FOA is to advance understanding of how public policy may serve as a tool for improving public health and welfare through its effects on behaviors and outcomes pertaining to alcohol and other drugs. This FOA is intended to support innovative research to examine policy effects that have the potential to lead to meaningful changes in public health. Research projects that may be supported by this FOA include, but are not necessarily limited to: causal analyses of the effects of one or multiple public policies; evaluations of the effectiveness of specific public policies as tools for improving public health through their effects on alcohol-, marijuana-, and other substance-related behaviors and outcomes; and research to advance methods and measurement used in studying relationships between public policies and alcohol-, marijuana-, and other substance-related behaviors and outcomes.

This Funding Opportunity Announcement (FOA), issued by the National Institute on Drug Abuse (NIDA), invites grant applications that propose longitudinal cohort studies to address emerging and/or high priority research on HIV/AIDS and substance abuse. This FOA will support the development and maintenance of new cohorts or the expansion of existing cohorts to address the natural and treated history of HIV infection in at-risk populations where substance use is a central factor. The intent of the FOA is to provide a strong resource platform for current and future collaborative efforts with other investigators to address emerging questions related to HIV infection, prevention, and treatment in the context of substance abuse, as well as to foster the creativity and efficiency of investigatorinitiated research goals.

 The National Institute on Drug Abuse supported a number of HIV/AIDS cohorts among substance abusing populations. These cohorts address emerging and high priority research on HIV/AIDS. These longitudinal cohorts serve as a strong resource platform for current and future collaborative efforts with other investigators to address emerging questions related to HIV infection, prevention, and treatment in the context of substance abuse, as well as to foster the creativity and efficiency of investigator-initiated research. Accomplishments by the NIDA-funded cohorts have been highly significant. Four of these cohorts (see below) will be terminated within a year if continued support is not provided. Therefore, the purpose of this Limited Competition Funding Opportunity Announcement (FOA) is to support the maintenance and expansion of these NIDA-funded cohorts to continue to address new emerging and/or high priority research on multidisciplinary aspects of HIV/AIDS and substance abuse.

This FOA supports highly innovative R01 applications on HIV/AIDS and drug abuse and complements the Avant-Garde Award Program for HIV/AIDS and Drug Use Research and the Avenir Award Program for Research on Substance Abuse and HIV/AIDS. The Avant-Garde award supports individuals who conduct high-risk, high-reward research and does not require a detailed research plan. The Avenir award is similar to the Avant-Garde award but focuses on support for early stage investigators. Applications submitted under this FOA are required to have a detailed research plan and preliminary data. This FOA focuses on innovative research projects that have the potential to open new areas of HIV/AIDS research and/or lead to new avenues for prevention and treatment of HIV/AIDS among substance abusers. The nexus with drug abuse should be clearly described. This FOA is open to both individual researchers and research teams and is not limited to any one area of research on HIV and substance use, but all studies must focus on NIH HIV/AIDS Research Priorities https://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-137.html.

HIV-associated neurological disorders (HAND) persist in up to 50% of HIV-patients even when HIV replication is suppressed by combination antiretroviral therapy (cART), which transformed HIV/AIDS from a fatal illness into a chronically managed long-term condition. HIV does not infect neurons, but infects microglia and macrophages in the brain, causing HAND associated neuropathology. HAND epitomizes a series of disorders include Asymptomatic Neurocognitive Impairment (ANI), Mild Neurocognitive Disorder (MND), and HIV-Associated Dementia (HAD). These neurocognitive deficits interfere with psychomotor speed and coordination, diminishing memory and executive functions, and reduce quality of life in long-standing aviremic HIV-positive patients. These clinical challenges mandate research for a better understanding of HIV neuropathology; however, currently there are no effective approaches for HIV-infected live human brain studies or realistic HIV-infected animal models for HIV neuropathology. Proposed projects MUST include the following components. Applications which lack these three components will be considered non-responsive to the FOA and will not be reviewed. The major thrust of the project MUST involve exploitation of induced microglia and cerebral organoids generated from patient derived iPSC lines to better understand the molecular and cellular mechanisms of HIV-Associated Neurocognitive Disorder (HAND). At least one aim or sub-aim MUST also involve either 1. opioid, cannabinoid, methamphetamine, nicotinic, dopaminergic, or other signaling pathways relevant to addictive substance use, or 2. exposure to addictive substances, or 3. analysis of samples from patients that have used addictive substances or have SUDs.

This FOA provides resources to support (a) pilot or feasibility studies of new or adapted interventions to prevent HIV infection among populations where substance use may be a contributing factor; (b) pilot or feasibility studies of new or adapted interventions to improve the care of HIV infection among populations where substance use is prevalent, including interventions that integrate treatment for substance use disorders and HIV infection; or (c) pilot or feasibility studies to increase the scale, uptake, delivery, and/or quality of HIV prevention or care interventions with established evidence of efficacy

Supported by the National Institute on Drug Abuse (NIDA) at the National Institutes of Health (NIH), EMF is inviting applications for its EMF/NIDA Mentor-Facilitated Training Award in Substance Use Disorders Science Dissemination. The award seeks works that addresses the overarching goals of EMF, including the promotion of knowledge of evidence-based SUD treatment among healthcare providers; the dissemination of substance use disorder research finding; the adoption of evidence-based approaches in medical settings, and the facilitation of the academic growth and development of future leaders in SUD management.

The goal of this FOA is to develop and test organizational and systems level interventions to determine how best to provide comprehensive, high quality, integrated, sustainable, cost-effective interventions to improve the health outcomes of PLWH with substance use disorders and other comorbid conditions. This FOA will support: 1) multidisciplinary research to enhance the adoption and integration of evidence-based screening and treatment of substance abuse in HIV centers and closely related medical settings; and 2) multidisciplinary research to increase the adoption and integration of HIV testing and linkage to HIV care in addiction treatment settings. In both HIV and addiction treatment settings, research to enhance the adoption and integration of treatment services for comorbid conditions (e.g. coinfections, psychiatric disorders) is encouraged.

As a key activity, INL promotes the development of a professional network of substance use disorder prevention and treatment service providers, policymakers, academic professionals, and other stakeholders (the "workforce") to encourage and promote evidence-based, effective drug demand reduction around the world. The purpose of this project is to support the development of an international membership organization that can provide online support and materials for networking and professionalization of the workforce, partner and collaborate with existing organizations to promote the dissemination of evidence-based best practices, and convene periodic global events that create opportunities for the substance use prevention and treatment workforce to receive training and meet other stakeholders. The recipient will also be responsible for maintaining a database of education providers and training activities carried out using materials developed by INL Demand Reduction programs, including those offered by other recipients of INL Demand Reduction program funding.

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIAAA/NIDA R25 program is to support educational activities that foster a better understanding of biomedical, behavioral, and clinical research on alcohol and other substance use disorders and their implications. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Outreach. Specifically, this FOA will support projects designed to engage practicing health care professionals in education about current and emerging knowledge derived from scientific research on the neurobiology, epidemiology, prevention, and/or treatment of alcohol and other substance use disorders and related health conditions.

The Drug-Free Communities Support Program provides grants to community coalitions working to prevent and reduce substance use among youth, which will ultimately reduce substance abuse among adults. The application deadline is March 29, 2018.